Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 344 results for antibiotics

  1. Care setting: What is the clinical and cost effectiveness of different models of care for the prevention and treatment of early-onset neonatal infection?

    guidance details Comes from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued

  2. Laparoscopic gastric plication for the treatment of severe obesity (HTG293)

    Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.

  3. Insertion of an epiretinal prosthesis for retinitis pigmentosa (HTG372)

    Evidence-based recommendations on insertion of an epiretinal prosthesis for retinitis pigmentosa. This involves inserting an implant into the eye that receives data from a small camera on the person's glasses and then stimulates healthy cells in the retina to see basic images.

  4. Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (HTG319)

    Evidence-based recommendations on photochemical corneal cross linkage using riboflavin and ultraviolet A for keratoconus. This involves using special eye drops and exposing the eye ultraviolet light, with the aim to strengthen the cornea.

  5. Clinical epidemiology of Lyme disease in the UK:- What are the incidence, presenting features, management and outcome of Lyme disease in the UK?

    population-basedstatistics. These statistics would enable interventions such as antibiotic treatment and service improvements to be...

  6. Preterm prelabour rupture of membranes: What are the relative risks and benefits of induced labour versus expectant management in women whose membranes have ruptured spontaneously between 34 and 37 weeks?

    membranes have ruptured, avoiding the need for induction. The value of antibiotic therapy and the administration of corticosteroids to...

  7. Impact of neonatal infection on the baby's family: What is the impact of neonatal infection on the health-related quality of life of the baby's family?

    guidance details Comes from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued

  8. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  9. Risk factors for and clinical indicators of early-onset infection: What is the risk of early-onset neonatal infection with maternal obesity and how does this change with increasing body mass index?

    guidance details Comes from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued

  10. Risk factors for and clinical indicators of early-onset infection: What is the accuracy of clinical prediction models for early-onset neonatal infection in the UK and what is their effectiveness in guiding management in the baby?

    guidance details Comes from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued

  11. Antimicrobial stewardship

    All NICE products on antimicrobial stewardship. Includes any guidance, advice and quality standards.

  12. Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the diagnostic accuracy of serial C-reactive protein testing to identify chorioamnionitis in women with P-PROM?

    of infection allows consideration of therapeutic strategies (including antibiotics and/or early birth). Effective treatment of infection...

  13. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

  14. myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)

    NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .